Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Oct;16(4):391–397. doi: 10.1111/j.1365-2125.1983.tb02183.x

The pharmacokinetics of frusemide are influenced by age.

F Andreasen, U Hansen, S E Husted, J A Jansen
PMCID: PMC1428049  PMID: 6626433

Abstract

After a 24 h control period 80 mg frusemide was given intravenously over 2 min to a group of young and a group of elderly healthy male volunteers. The serum concentration of frusemide and the excretion in urine of the drug and a glucuronidated metabolite were followed for 24 h. The elimination of the drug from serum was described by an open two compartment model. The serum clearance (CLs) was 170 +/- 19 ml min-1 in the young and 129 +/- 11 ml min-1 in the elderly (P less than 0.01) and the average renal clearance (CLr) was 67% of CLs in the young and 58% of CLs in the elderly (NS). The average amount of unchanged frusemide in the urine during the first 30 min was 30 +/- 6 mg in the young but only 20 +/- 4 mg in the elderly (P less than 0.01). The albumin concentration in serum was 15% lower in the elderly but on the average the protein bound fraction of frusemide was 98.6% in both groups. The Vd ss did not differ between the two age groups (0.130 1 kg-1) but the elimination half-life was 70 +/- 20 min in the young and 102 +/- 33 min in the elderly (P less than 0.05). In the young 11.4 +/- 5.0 mg frusemide was excreted as a glucuronidated compound whereas this figure was only 5.4 +/- 2.9 mg in the elderly (P less than 0.01). It is concluded that the age-related changes in the fate of unchanged frusemide in the organism mainly can be explained by a reduction in the tubular secretion of the drug which in turn may be caused by a reduction in renal plasma flow.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen F., Behrendt F. B., Moustgaard L. On the consumption of reimbursed drugs in Denmark. A pharmacological-epidemiological analysis based on 1,395 prescriptions in the county of Aarhus from April 1, 1974 to March 31, 1975. Dan Med Bull. 1978 Feb;25(2):67–78. [PubMed] [Google Scholar]
  2. Andreasen F., Christensen C. K., Jacobsen F. K., Jansen J., Mogensen C. E., Pedersen O. L. The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. Eur J Clin Invest. 1982 Jun;12(3):247–255. doi: 10.1111/j.1365-2362.1982.tb01000.x. [DOI] [PubMed] [Google Scholar]
  3. Andreasen F., Christensen C. K., Jakobsen F. K., Mogensen C. E. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol (Copenh) 1981 Sep;49(3):223–229. doi: 10.1111/j.1600-0773.1981.tb00897.x. [DOI] [PubMed] [Google Scholar]
  4. Andreasen F., Hansen H. E., Mikkelsen E. Pharmacokinetics of furosemide in anephric patients and in normal subjects. Eur J Clin Pharmacol. 1978 Mar 17;13(1):41–48. doi: 10.1007/BF00606681. [DOI] [PubMed] [Google Scholar]
  5. Andreasen F., Husted S. The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon. Acta Pharmacol Toxicol (Copenh) 1980 Sep;47(3):202–207. doi: 10.1111/j.1600-0773.1980.tb01560.x. [DOI] [PubMed] [Google Scholar]
  6. Andreasen F., Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15–22. doi: 10.1007/BF00561400. [DOI] [PubMed] [Google Scholar]
  7. Andreasen F., Sigurd B., Steiness E. Effect of probenecid on excretion and natriuretic action of furosemide. Eur J Clin Pharmacol. 1980 Nov;18(6):489–495. doi: 10.1007/BF00874661. [DOI] [PubMed] [Google Scholar]
  8. Benet L. Z. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm. 1979 Feb;7(1):1–27. doi: 10.1007/BF01059438. [DOI] [PubMed] [Google Scholar]
  9. Burg M., Stoner L., Cardinal J., Green N. Furosemide effect on isolated perfused tubules. Am J Physiol. 1973 Jul;225(1):119–124. doi: 10.1152/ajplegacy.1973.225.1.119. [DOI] [PubMed] [Google Scholar]
  10. Chennavasin P., Seiwell R., Brater D. C., Liang W. M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 1979 Aug;16(2):187–195. doi: 10.1038/ki.1979.120. [DOI] [PubMed] [Google Scholar]
  11. Christensen J. H., Andreasen F., Jansen J. A. Pharmacokinetics and pharmacodynamics of thiopentone, A comparison between young and elderly patients. Anaesthesia. 1982 Apr;37(4):398–404. doi: 10.1111/j.1365-2044.1982.tb01148.x. [DOI] [PubMed] [Google Scholar]
  12. Cutler R. E., Blair A. D. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet. 1979 Jul-Aug;4(4):279–296. doi: 10.2165/00003088-197904040-00002. [DOI] [PubMed] [Google Scholar]
  13. Homeida M., Roberts C., Branch R. A. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther. 1977 Oct;22(4):402–409. doi: 10.1002/cpt1977224402. [DOI] [PubMed] [Google Scholar]
  14. Perez J., Sitar D. S., Ogilvie R. I. Biotransformation of furosemide in patients with acute pulmonary edema. Drug Metab Dispos. 1979 Nov-Dec;7(6):383–387. [PubMed] [Google Scholar]
  15. Rane A., Villeneuve J. P., Stone W. J., Nies A. S., Wilkinson G. R., Branch R. A. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther. 1978 Aug;24(2):199–207. doi: 10.1002/cpt1978242199. [DOI] [PubMed] [Google Scholar]
  16. Rose H. J., Pruitt A. W., Dayton P. G., McNay J. L. Relationship of urinary furosemide excretion rate to natriuretic effect in experimental azotemia. J Pharmacol Exp Ther. 1976 Dec;199(3):490–497. [PubMed] [Google Scholar]
  17. Smith D. E., Lin E. T., Benet L. Z. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos. 1980 Sep-Oct;8(5):337–342. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES